New cocktail aims to tackle tough pancreatic cancer
NCT ID NCT06941857
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a new drug called NC410 combined with standard chemotherapy (FOLFIRINOX) and immunotherapy drugs (nivolumab with or without ipilimumab) in 20 people with metastatic pancreatic cancer who have not had prior treatment. The main goal is to check safety and identify any unexpected side effects. Researchers will also track how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NC410 (a biologic) plus FOLFIRINOX chemotherapy (oxaliplatin, irinotecan, folinic acid, fluorouracil) plus nivolumab with or without ipilimumab
What this could lead to
If successful, this could point toward a new combination treatment that improves outcomes for people with metastatic pancreatic cancer.
What could go wrong
This is a small, early-phase trial focused on safety, not yet proven to work. The combination may cause significant side effects and may not improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact